Halozyme Names Chief Scientific Officer

From DCAT Value Chain Insights (VCI)

By People On The Move posted 08-28-2015 17:41


Halozyme Therapeutics, Inc., a biotechnology company developing oncology and drug-delivery therapies, has named Michael J. LaBarre, PhD. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed as a research fellow for the company.

The move broadens Dr. LaBarre's responsibilities to include research and development of early pipeline assets, in addition to his role managing product development and Enhanze platform partnerships. Enhanze is Halozyme's proprietary delivery platform using recombinant human hyaluronidase.

Prior to joining Halozyme in 2008, Dr. LaBarre served as vice president, product development at Paramount BioSciences LLC; director, analytical and protein biochemistry, discovery research at Biogen Idec; and director analytical and formulation sciences, research and development at IDEC Pharmaceuticals.

Source: Halozyme Therapeutics 


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription